NASDAQ · SPRB
Spruce Biosciences, Inc.
$46.82-$0.17 (-0.36%)
Spruce Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.71% below the high.
Loading market information…
NASDAQ · VTVT · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
vTv Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 40.05% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
vTv Therapeutics Inc.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of -$1.07. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow vTv Therapeutics Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
vTv Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on creating orally administered treatments, with a significant emphasis on diabetes. Its pipeline features lead candidates such as TTP399, an oral, small-molecule, liver-specific glucokinase activator targeting Type 1 diabetes. Another key investigational drug is HPP737, an oral phosphodiesterase type 4 (PDE4) inhibitor that does not cross the blood-brain barrier (non-CNS penetrant), designed to treat inflammatory conditions and psoriasis. Beyond these, vTv Therapeutics' broader clinical portfolio includes: TTP273, an oral small-molecule GLP-1 receptor agonist addressing postprandial glucose excursions in cystic fibrosis-related diabetes. HPP3033, which employs a non-electrophilic strategy to activate the Nrf2 pathway for chronic conditions linked to oxidative stress. Azeliragon, a RAGE antagonist being evaluated for inflammatory lung disorders, notably severe COVID-19, alongside pancreatic and breast cancers. HPP971, an Nrf2 activator aimed at renal diseases, developed in collaboration with pharmaceutical partners. Furthermore, vTv holds a licensing agreement with Reneo Pharmaceuticals, Inc. for the development and commercialization of its peroxisome proliferation-activated receptor delta agonist program, which features the compound HPP593. The company has also established various other licensing and research collaborations with entities such as Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., Newsoara Biopharma Co., Ltd., JDRF International, and Novo Nordisk A/S. Established in 2015, vTv Therapeutics is headquartered in High Point, North Carolina, and operates as a subsidiary of MacAndrews & Forbes Incorporated.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:41 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $0.00 |
| Q4 2024 | Mar 20, 2025 | -$0.55+36.78% vs estimate | $17.00K |
|---|
| Q3 2024 | Nov 12, 2024 | -$0.88+75.56% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
14 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 1 contributors · Median target $42.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$46.82-$0.17 (-0.36%)
Spruce Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.71% below the high.
$0.49-$0.05 (-9.43%)
Outlook Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.57% below the high.
$2.66-$0.03 (-1.12%)
NRx Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 47.43% below the high.
$2.00+$0.04 (+2.04%)
Fortress Biotech, Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.85% below the high.
$1.30+$0.05 (+4.0%)
OS Therapies Incorporated’s quoted price sits in the lower half of its reported 52-week range, 42.22% below the high.
$10.88+$0.08 (+0.69%)
MiNK Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 35.76% below the high.
$1.10+$0.04 (+3.77%)
Werewolf Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 53.78% below the high.
$1.19-$0.01 (-0.42%)
Gain Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.58% below the high.
